Advertisement
Document › Details
Proteros Biostructures GmbH. (6/2/21). "Press Release: Proteros Enters into Oncology Collaboration and License Agreement with AstraZeneca". Martinsried.
Proteros to receive research funding and milestone payments plus royalties
Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.
The collaboration brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca’s expertise in target biology and medicinal chemistry to jointly discover novel lead compounds which will be further developed, manufactured, and commercialized by AstraZeneca.
Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.
“We believe that advances in epigenomic capabilities will bring forward the next wave of innovation in cancer development through the discovery and development of novel small molecules,” said Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, AstraZeneca. “Proteros’ proprietary discovery platform enables us to screen epigenetic targets in a physiologically relevant setting, supporting accelerated discovery and development of the next wave of anti-cancer medicines.”
“We are delighted AstraZeneca has selected Proteros to act as their discovery engine for a number of novel and very relevant oncology targets,” said Dr Torsten Neuefeind, Proteros’ CEO. “These types of targets pose a number of challenges that Proteros’ discovery platform is uniquely positioned to overcome.”
About Proteros biostructures GmbH
Proteros is a privately held early-stage services provider in structure-based drug discovery with a cutting-edge discovery engine tailored to unlock even the most technically challenging targets. Proteros’ work is built on scientific excellence and supports its clients to reach the right results and accelerate their overall research timelines. Proteros supports most of the world’s 20 largest pharma companies and more than 250 pharmaceutical and biotech partners in the US, Europe and Japan.
For more information please visit www.proteros.com.
Proteros contact information
Dr. Torsten Neuefeind
Chief Executive Officer
Phone: +49 89 700761-0
Email: info@proteros.com
Record changed: 2023-06-05 |
Advertisement
More documents for Proteros (Group)
- [1] Proteros Biostructures GmbH. (9/6/23). "Press Release: Proteros Biostructures and Orion Pharma Agree on a Long-term Multi-target Collaboration". Martinsried....
- [2] Proteros Biostructures GmbH. (1/9/23). "Press Release: Proteros Receives Minority Investment from Private Equity Firm Inflexion". Martinsried....
- [3] Proteros Biostructures GmbH. (10/25/22). "Press Release: Proteros and Adrestia Initiate Multi-target Partnership to Discover First-in-class Drugs for Intractable Genetic Diseases". Martinsried....
- [4] Proteros Biostructures GmbH. (5/16/22). "Press Release: Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca". Munich....
- [5] Silence Therapeutics plc. (6/21/18). "Press Release: Silence Therapeutics Strengthens Board and Leadership Team"....
- [6] Proteros Biostructures GmbH. (12/6/17). "Press Release: Proteros Names Dave Lemus as New Executive Board Member". Munich....
- [7] Proteros Biostructures GmbH. (7/27/17). "Press Release: Proteros Enters into New Research Collaboration with Johnson & Johnson Innovation on Sub-class of Epigenetic targets". Dublin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top